C-FSZHPretzel Therapeutics
mitochondrial bioenergetics, mtDNA modulation, small molecules
modulatingsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-FSZH
C-FSZHC-FSZHmitochondrial bioenergetics, mtDNA modulation, small molecules
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Pretzel Therapeutics mitochondrial bioenergetics, mtDNA modulation, small molecules
Pretzel Therapeutics is a biotechnology company harnessing mitochondrial biology to develop therapies for diseases associated with bioenergetic dysregulation. Its approaches control replication and transcription of mitochondrial DNA to modulate disease processes. The company lists programs targeting POLG, SAMHD1 and POLRMT across rare/neurodegenerative and obesity/metabolic indications.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Pretzel Therapeutics — Translational · Lower middle. Derived deterministically from 13 extracted project(s). Most-advanced status: phase 1. Band: translational. Modifiers: +5 depth (2 programs at…
Source: Deterministic